WNT10-derived peptide and use thereof
The present invention relates to a WNT10-derived peptide, a composition for improving hair loss and skin conditions using the same, and a composition for treating a WNT10 signal transduction pathway-related disorder and DKK-1 protein-induced disorder the same. WNT10-derived peptide of the present invention possesses identical or similar activities to natural-occurring WNT10, and has much higher stability and skin penetration potency than natural-occurring WNT10. Therefore, the composition containing the present peptide not only shows excellent effects on improvement in hair loss (for example, promotion of hair growth or production of hair), but also has superior efficacies on treatment of a WNT10 signal transduction pathway-related disorder and a DKK-1 protein-induced disorder. In addition, the outstanding activity and stability of the present peptide described above may be greatly advantageous in application to pharmaceutical compositions, quasi-drugs and cosmetics.
1. A peptide comprising the amino acid sequence of SEQ ID NO:1.
2. The peptide of claim 1 , wherein the peptide is derived from a human WNT10.
3. The peptide of claim 1 , wherein the peptide facilitates cell proliferation in keratinocytes and fibroblasts.
4. The peptide of claim 1 , wherein the peptide promotes fibronectin expression.
5. The peptide of claim 1 , wherein the peptide transfers β-catenin into a nucleus.
6. A method for treating hair loss, comprising administering to a subject a composition comprising the peptide of claim 1 as an active ingredient.
7. The method of claim 6 , wherein the composition further comprises a peptide having the amino acid sequence of (i) SEQ ID NO:2, (ii) SEQ ID NO:3 and SEQ ID NO:4 linked by an amino acid or a peptide linker, or (iii) both peptides defined by (i) and (ii).
8. The method of claim 6 , wherein prevention or the treatment of the hair loss is promotion of hair growth or production of hair.
9. A method for promoting fibroblast or keratinocyte proliferation, or elevating the level of fibronectin, comprising administering to a subject a composition comprising the peptide of claim 1 as an active ingredient.
10. The method of claim 9 , wherein the composition further comprises a peptide having the amino acid sequence of (i) SEQ ID NO:2, (ii) SEQ ID NO:3 and SEQ ID NO:4 linked by an amino acid or a peptide linker, or (iii) both peptides defined by (i) and (ii).
11. The method of claim 9 , wherein the administration of the composition results in a decrease in the number and/or severity of wrinkles, an increase in skin elasticity, an increase in skin moisture, accelerated wound healing, or regeneration of skin.
12. A method for treating a WNT10 signal transduction pathway-related disorder, comprising administering to a subject a composition comprising the peptide of claim 1 as an active ingredient.
13. The method of claim 12 , wherein the composition further comprises a peptide having the amino acid sequence of (i) SEQ ID NO:2, (ii) SEQ ID NO:3 and SEQ ID NO:4 linked by an amino acid or a peptide linker, or (iii) both peptides defined by (i) and (ii).
14. The method of claim 12 , wherein the WNT10 signal transduction pathway-related disorder comprises a bone disorder or a tumor disorder.
15. The method of claim 14 , wherein the bone disorder is selected from the group consisting of a disease associated with bone development, a bone fracture, a senile bone loss, chondrodystrophia, hypercalcemia, hyperostosis, osteogenesis imperfect, osteomalacia, osteomyelitis, osteoporosis, Paget's disease of bone, osteoarthritis and rachitis.
16. A method for treating a DKK-1 protein-induced disorder, comprising administering to a subject a composition comprising the peptide of claim 1 as an active ingredient.
17. The method of claim 16 , wherein the composition further comprises a peptide having the amino acid sequence of (i) SEQ ID NO:2, (ii) SEQ ID NO:3 and SEQ ID NO:4 linked by an amino acid or a peptide linker, or (iii) both peptides defined by (i) and (ii).
18. The method of claim 16 , wherein the DKK-1 protein-induced disorder comprises diabetes or muscle recovery or regeneration.
19. The method of claim 18 , wherein the diabetes is associated with insulin resistance and hypoglycemia.